Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc

BIOASIS TECHNOLOGIES INC., a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, announced the following amendments to the terms of the previously announcement arrangement agreement with Midatech Pharma plc:

• Midatech is no longer required to seek delisting from AIM following completion of the arrangement; and
• the US$750,000 bridge loan to be provided by Midatech to Bioasis will now be advanced in three equal tranches of US$250,000 (on December 19, 2022, January 3, 2023 and February 6, 2023) instead of the entire amount being advanced immediately, as previously contemplated.